leadf
logo-loader
viewReNeuron Group PLC

ReNeuron assessing potential of emerging cell technology in the coronavirus fight

It has developed a line of the human exosomes that can deliver a medically relevant payload; viral vaccines, for example

ReNeuron Group PLC -

ReNeuron Group PLC (LON:RENE) has said it is assessing the potential of an emerging cell technology to help in the fight against the coronavirus (COVID-19).

It has developed a line of the human exosomes that can deliver a medically relevant payload; viral vaccines, for example.

“Previously presented, unpublished data show that ReNeuron's exosomes can be loaded with biologically active cargo and delivered preferentially to certain specific sites in the body,” the company said in a statement.

“This research is in its initial stages, the goal being to establish whether an increase in the potency of SARS-CoV-2 coronavirus vaccines in development can be enhanced in this way, utilising ReNeuron's established expertise in exosome isolation, modification and manufacture at scale.”

The insight was provided alongside a wider update on progress in the face of the COVID-19 outbreak, which has led to wholesale lockdowns on both sides of the Atlantic.

The stem cell specialist said the disruption will inevitably lead to delays in the recruitment of patients to trials of its treatments for people with stroke disability and a degenerative eye condition called retinitis pigmentosa. 

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

ReNeuron’s priority internal research, meanwhile, is progressing to “current timelines”. The firm said it is adhering to safety guidelines in the labs with a rota system and, where possible, work is being done from home.

“The safety of employees, suppliers, clinical trial participants and all other people with whom the company interacts is of over-riding importance to the company,” investors were told.

Finally, ReNeuron's exclusive licensing partner in China, Shanghai Fosun, has recently filed to open clinical sites to take part in the ongoing PISCES III clinical trial in stroke disability.

Quick facts: ReNeuron Group PLC

Price: 86 GBX

LSE:RENE
Market: LSE
Market Cap: £27.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

ReNeuron Group PLC: Proactive One2One Virtual Conference

ReNeuron Group PLC's (LON:RENE) Michael Hunt presents at the Proactive One2One Virtual Conference. ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

on 29/8/20

2 min read